Bentyl (Dicyclomine) is Contraindicated in Children Under 6 Months and Not Recommended for Routine Pediatric Use
Bentyl should NOT be used in children under 6 months of age, and its safety and efficacy have not been established in the pediatric population. The FDA drug label explicitly contraindicates dicyclomine in infants less than 6 months and states that safety and efficacy in children have not been established 1.
Critical Safety Information
Absolute Contraindications
- Infants < 6 months of age: This is a black box-level contraindication 1
- Nursing mothers: The drug is contraindicated due to potential infant exposure 1
Why This Matters for Morbidity and Mortality
The FDA warnings specifically highlight that dicyclomine has been associated with:
- Acute episodes of apnea in infants 2
- Seizures and coma in young children 1
- CNS toxicity including confusion, disorientation, and hallucinations 1
These serious adverse events directly impact mortality risk in the youngest patients, which is why the contraindication exists.
Historical Context (Not Current Recommendations)
While older research from the 1980s studied dicyclomine for infantile colic at doses of 5 mg given 3-4 times daily in infants over 6 months 3, this practice has been abandoned due to safety concerns. One case report documented a SIDS death in an infant with therapeutic dicyclomine levels, raising concerns about the drug's role in respiratory depression 2.
No Established Pediatric Dosing
There is no FDA-approved weight-based (mg/kg) dosing for children of any age. The drug label does not provide pediatric dosing recommendations because safety and efficacy studies were never completed in this population 1.
Clinical Bottom Line
- Do not prescribe dicyclomine to any child under 6 months - this is an absolute contraindication with potential fatal consequences 1
- Avoid dicyclomine in older children - no established safe and effective dosing exists
- Consider alternative therapies for gastrointestinal spasm in pediatric patients that have established pediatric safety profiles
The lack of established pediatric dosing, combined with documented serious adverse events including apnea and potential SIDS association, makes dicyclomine inappropriate for pediatric use regardless of age or weight.